These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20524820)

  • 1. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.
    Evangeli M; Mughal K; Porter JB
    Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia.
    Vosper J; Evangeli M; Porter JB; Shah F
    Hemoglobin; 2018 Jan; 42(1):30-36. PubMed ID: 29521137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
    J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.
    Trachtenberg FL; Gerstenberger E; Xu Y; Mednick L; Sobota A; Ware H; Thompson AA; Neufeld EJ; Yamashita R;
    Qual Life Res; 2014 Oct; 23(8):2277-88. PubMed ID: 24682717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beliefs about chelation among thalassemia patients.
    Trachtenberg FL; Mednick L; Kwiatkowski JL; Neufeld EJ; Haines D; Pakbaz Z; Thompson AA; Quinn CT; Grady R; Sobota A; Olivieri N; Horne R; Yamashita R;
    Health Qual Life Outcomes; 2012 Dec; 10():148. PubMed ID: 23216870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review.
    Locke M; Reddy PS; Badawy SM
    Hemoglobin; 2022 Jul; 46(4):201-213. PubMed ID: 35930250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beliefs and Adherence Associated With Oral and Infusion Chelation Therapies in Jordanian Children and Adolescents With Thalassemia Major: A Comparative Study.
    Abu Shosha GM
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):210-214. PubMed ID: 30585946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT; Tsai MY; Peng CT; Wu KH
    Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
    Mudiyanse RM
    Hemoglobin; 2006; 30(2):275-89. PubMed ID: 16798653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.